Karamali Bandealy
Rheumatology · Kissimmee, FLNPI 1982686135
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 373 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 23.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,872 and has fallen 98.3% since, to $33 in 2025. That places this record below the midpoint for rheumatology clinicians in FL, where the typical reported total is $6,335.
Across 373 payments — averaging $17.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$2K
- AbbVie$1K
- Novartis$871
- Johnson & Johnson$740
- Pfizer$416
- E.r. Squibb & Sons, L.L.C.$410
- plus $2K from 16 others
Across 249 payments — averaging $2731.70 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sun Pharmaceutical Industries Inc.$426K
- Eli Lilly$143K
- E.r. Squibb & Sons, L.L.C.$90K
- Boehringer Ingelheim$12K
- Navidea Biopharmaceuticals, Inc.$7K
- Boehringer Ingelheim France S.a.s.$3K
What the payments were for
- Food & beverage$6,662100%
- Education$180%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 95 | $1,584 |
| AbbVie | 55 | $1,004 |
| Novartis | 47 | $871 |
| Johnson & Johnson(3 entities) | 42 | $740 |
| Pfizer | 27 | $416 |
| E.r. Squibb & Sons, L.L.C. | 23 | $410 |
| UCB, Inc. | 23 | $332 |
| Lilly USA, LLC | 12 | $274 |
| GSK | 11 | $236 |
| Sanofi | 8 | $153 |
| Genentech USA, Inc. | 8 | $138 |
| Janssen Scientific Affairs, LLC | 1 | $125 |
| AstraZeneca | 6 | $106 |
| Aurinia Pharma U.S., Inc. | 3 | $68 |
| Mallinckrodt Hospital Products Inc. | 2 | $46 |
| Boehringer Ingelheim | 3 | $44 |
| Bristol Myers Squibb | 2 | $44 |
| Actelion Pharmaceuticals US, Inc. | 1 | $21 |
| Antares Pharma, Inc. | 1 | $19 |
| Ferring Pharmaceuticals Inc. | 1 | $18 |
| ANI Pharmaceuticals, Inc. | 1 | $16 |
| Sobi, Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SIMPONI ARIA$125
- STELARA$125
- Tremfya$125
How this compares
$6,680 in reported general payments places this provider in the 50th percentile of 453 rheumatology providers in Florida.
Other rheumatology in Kissimmee
- Alvin WellsDestin$2.4M
- Guillermo ValenzuelaPlantation$1.5M
- Julio Gonzalez-PaoliTampa$1.4M
- Ernesto RodriguezZephyrhills$958K
- Vinicius Costa Diniz DominguesDaytona Beach$921K
- Jonathan GreerBoynton Beach$757K
- Jigar ShahMargate$750K
- Rachel TateHollywood$729K
- Howard BuschLoxahatchee$717K
- Michael WeitzMiami$658K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.